Early research (Phase 1)Study completedNCT00879385What this trial is testingKRAS Wild-type Metastatic Colorectal Cancer TrialWho this might be right forColorectal Cancer University of Utah 21
Early research (Phase 1)Study completedNCT06056024What this trial is testingTest How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and OesophagusWho this might be right forSolid Tumor, KRAS Mutation Boehringer Ingelheim 47
Testing effectiveness (Phase 2)Study completedNCT00842257What this trial is testingPanitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal CancerWho this might be right forColorectal Cancer Massachusetts General Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT01522612What this trial is testingColorectal Cancer (CRC) Cetuximab Elderly FrailWho this might be right forColorectal Cancer Metastatic European Organisation for Research and Treatment of Cancer - EORTC 5
Early research (Phase 1)Active Not RecruitingNCT01787500What this trial is testingVemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by SurgeryWho this might be right forBRAF NP_004324.2:p.V600XKRAS wt AlleleMetastatic Malignant Solid Neoplasm+4 more M.D. Anderson Cancer Center 33
Large-scale testing (Phase 3)Study completedNCT01550055What this trial is testingStudy of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer Shanghai Zhangjiang Biotechnology Limited Company 512
Testing effectiveness (Phase 2)Ended earlyNCT01523639What this trial is testingA Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated SteatosisWho this might be right forColorectal CancerSteatohepatitis Austrian Breast & Colorectal Cancer Study Group 8
Testing effectiveness (Phase 2)Ended earlyNCT01925274What this trial is testingPF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer Pfizer 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT04625270What this trial is testingAvutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS MutationWho this might be right forLow Grade Ovarian Serous AdenocarcinomaOvarian Cancer Verastem, Inc. 225
Testing effectiveness (Phase 2)Active Not RecruitingNCT04117945What this trial is testingRegorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal CancerWho this might be right forBRAF V600E NegativeKRAS Gene Mutation NegativeLocally Advanced Unresectable Colorectal Adenocarcinoma+10 more Academic and Community Cancer Research United 22
Testing effectiveness (Phase 2)Study completedNCT01652482What this trial is testingSafety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)Who this might be right forColorectal Cancer Genentech, Inc. 135
Testing effectiveness (Phase 2)Study completedNCT00861120What this trial is testingPanitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-typeWho this might be right forEpithelial Ovarian Cancer Vejle Hospital 33
Testing effectiveness (Phase 2)Ended earlyNCT01504477What this trial is testingPanitumumab and Bortezomib for Patients With Advanced Colorectal CancerWho this might be right forColorectal Cancer Georgetown University 6
Not applicableEnded earlyNCT01134666What this trial is testingAn Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal CancerWho this might be right forColorectal Neoplasms Merck KGaA, Darmstadt, Germany 165
Testing effectiveness (Phase 2)Study completedNCT00803647What this trial is testingA Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the LiverWho this might be right forMetastatic Colorectal Cancer NSABP Foundation Inc 20
Testing effectiveness (Phase 2)UnknownNCT01384994What this trial is testingPanitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type PatientsWho this might be right forColorectal CancerKRAS WildtypeAfter Resection of Liver Metastases PD Dr. med. Volker Heinemann 111
Testing effectiveness (Phase 2)Looking for participantsNCT05887492What this trial is testingStudy of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsWho this might be right forNon Small Cell Lung CancerSolid Tumors, AdultLung Cancer+1 more Tango Therapeutics, Inc. 126
Early research (Phase 1)Ended earlyNCT01871311What this trial is testingA Phase I Study of Nilontinib and Cetuximab in Patients With Solid TumorsWho this might be right forColorectal CancerHead and Neck Cancer Georgetown University 15
Testing effectiveness (Phase 2)Study completedNCT01202409What this trial is testingCAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of VaterWho this might be right forGastrointestinal Cancer M.D. Anderson Cancer Center 19
Testing effectiveness (Phase 2)Study completedNCT00819780What this trial is testingPEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) TumorsWho this might be right forColon CancerColorectal CancerRectal Cancer+1 more Amgen 285